CorMedix Analyst Says Investors Could Be Further Rewarded
1. CRMD's LDO customer begins orders; implementation set for 2025. 2. DefenCath's target patient base to grow by 50%; potential for more expansion. 3. Second-quarter net sales guidance increased to $35-$40 million. 4. HC Wainwright initiated coverage with a Buy rating and $20 price target. 5. CRMD anticipates long-term revenue growth despite initial uncertainty.